HIV与肛门癌的治疗结果：一家机构的经验

HIV and anal cancer outcomes: a single institution's experience.

作者信息

Hogg Melissa E, Popowich Daniel A, Wang Ed C, Kiel Kristina D, Stryker Steven J, Halverson Amy L

机构信息

Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

出版信息

Dis Colon Rectum. 2009 May;52(5):891-7. doi: 10.1007/DCR.0b013e31819eefa6.

DOI:10.1007/DCR.0b013e31819eefa6

PMID:19502853

Abstract

PURPOSE

The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal.

METHODS

A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006.

RESULTS

Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer. The median follow-up was 38 months. Eighty-five percent of HIV-negative patients and 81 percent of HIV-positive were identified as complete responders at 6 weeks after completion of combined modality therapy. Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009). Overall survival for HIV-negative and HIV-positive patients was 71 percent and 73 percent, respectively.

CONCLUSIONS

HIV-positive patients respond equally to combined modality therapy but have recurrences more frequently than patients who are HIV negative. Overall survival in these two groups is equivalent.

摘要

目的

本研究旨在确定人类免疫缺陷病毒（HIV）感染状态对肛管鳞状细胞癌治疗结果的影响。

方法

对1996年1月至2006年12月期间在某单一学术机构接受治疗的所有肛管鳞状细胞癌患者进行回顾性研究。

结果

我们的检索确定了87例（21例HIV阳性）浸润性鳞状细胞癌患者。中位随访时间为38个月。在联合治疗结束6周时，85%的HIV阴性患者和81%的HIV阳性患者被确定为完全缓解者。6个月后，8%的HIV阴性患者和29%的HIV阳性患者出现疾病复发（P = 0.0009）。HIV阴性和HIV阳性患者的总生存率分别为71%和73%。